65,437 trials
Dry Eye Disease
Primary: Percentage of Patients With Complete Clearing of Corneal Staining at Month 12 — 33.3 Percentage of Patients
Bipolar Disorder · Bipolar Affective Psychosis · Mania
Primary: Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to End of Treatment (Day 21) — -20.72 Scores on a scale
Carcinoma, Hepatocellular
Primary: Tumour Stabilisation Rate — 5.3; 16.0; 8.7 percentage of patients
Carcinoma, Transitional Cell · Bladder Cancer · Bladder Neoplasm
Primary: Objective Response Rate (ORR) — 1 participants
Cardiovascular Diseases
Primary: Systolic Blood Pressure — 127; 129; 128; 117 mmHg — p=<0.05
Intraventricular Hemorrhage
Primary: 30-day Mortality — 1; 1; 6 Number of participants
Healthy
Primary: The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema). — 0; 51; 0; 0 injections
Atrial Fibrillation · Stroke · Embolism
Primary: The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority) — 188; 241 Patients — p=<0.001
Healthy
Primary: Shuttle Walk Test Distance — 812 m
Adenocarcinoma of the Prostate · Stage I Prostate Cancer · Stage II Prostate Cancer
Primary: Concentration of Lycopene in Prostatic Surgical Tissue — 0.663; 0.378; 0.723; 0.165 ug/dL
Carcinoma, Pancreatic Ductal
Primary: Overall Survival (OS) — 36.9; 35.8 Weeks — p=0.5436
Dyslipidemia · Kidney Disease
Primary: Median Percent Change in Triglycerides From Baseline to Week 8. — -38.0; -22.4 percent change — p=<0.001
Total Knee Arthroplasty · Osteoarthritis
Primary: Postoperative Range of Motion (ROM) — 119.1; 120.7 degrees
Schizophrenia
Primary: Positive Symptom Item Scores by Week and Treatment Group — 15.5; 15.5; 14.6; 15.1 units on a scale
Lung Cancer · Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung
Primary: Immune-related Progression-free Survival (irPFS) in Participants With Nonsmall-cell Lung Cancer (NSCLC) Per Immune-related Response Criteria (irRC) — 5.52; 5.68; 4.63…